Immunotherapy shows promise for mysterious cancers

NCT ID NCT03752333

Completed Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 10 times

Summary

This study tested the drug pembrolizumab in 35 people with cancer of unknown primary (CUP), a cancer that starts in an unknown location. The goal was to see if the drug could shrink tumors. Participants received pembrolizumab intravenously, and doctors measured tumor response using CT scans. The trial found that some patients had their tumors shrink or stabilize, but it is not a cure and ongoing management is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Gastrointestinal Units, The Royal Marsden NHS Foundation Trust (Sutton and Chelsea)

Sutton, Surrey, United Kingdom
Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom
Hammersmith Hospital - Imperial College Healthcare NHS Trust

Hammersmith, London, W12 0HS, United Kingdom

Conditions

Explore the condition pages connected to this study.

CANCER OF UNKNOWN PRIMARY SITE